The Guardant360 assay, the most widely used comprehensive liquid biopsy, was introduced in 2014. It has been ordered more than 50,000 times by more than 3,500 oncologists to look for somatic genomic alterations associated with targeted therapies in the tumor DNA of patients with advanced cancer. It is supported by more than 30 peer-reviewed journal publications that address its analytical validity, clinical validity, and clinical utility.
About Guardant Health
Guardant Health is focused on conquering cancer by using its breakthrough blood-based assays, vast data sets, and advanced analytics. Using both molecular and digital tools, Guardant Health is addressing challenges across the cancer care continuum. The company has raised more than $500 million from leading investors. Its first product, the Guardant360 assay, came to market in 2014, and is now the most widely ordered comprehensive liquid biopsy commercially available. In 2016, it announced Project LUNAR, an effort to apply Guardant Health's technology platform to early detection, recurrence monitoring, and assessing minimal residual disease. Guardant Health and Guardant360 are registered trademarks of Guardant Health, Inc.
Ad Statistics
Times Displayed: 22281
Times Visited: 445 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
SOURCE Guardant Health
Back to HCB News
